Want to see NZ:AFT full AI Analyst Report?
Top Page
AFT Pharmaceuticals Ltd.
(AFT)
Select Model
Select Model
Rating:54Neutral
Price Target:
$4.50
Action:N/A
Date:10/05/26
The score is primarily held back by the sharp downturn in the latest cash flow results and related balance-sheet risk (higher debt alongside negative free cash flow), despite strong revenue growth and stable gross margins. Technical indicators are broadly neutral and valuation appears relatively expensive, which limits upside without a clear improvement in cash generation and profitability.
Positive Factors
Strong revenue growth
A sustained rise in revenue across five annual periods indicates expanding product adoption and international commercial reach. The latest acceleration, together with growth across territories, provides a stronger foundation for reinvestment, operating leverage, and continued scale over the next several quarters.
Negative Factors
Negative cash generation
The reversal to negative operating and free cash flow weakens cash conversion and increases reliance on external financing or balance-sheet resources. Until generation normalises, AFT has less flexibility to fund product development, absorb execution setbacks, or pursue growth while maintaining financial resilience.
Read all positive and negative factors
Positive Factors
Negative Factors
Strong revenue growth
A sustained rise in revenue across five annual periods indicates expanding product adoption and international commercial reach. The latest acceleration, together with growth across territories, provides a stronger foundation for reinvestment, operating leverage, and continued scale over the next several quarters.
Read all positive factors
AFT Pharmaceuticals Ltd. (AFT) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$450.96M
Dividend Yield0.68%
Average Volume (3M)23.45K
Price to Earnings (P/E)31.0
Beta (1Y)-0.02
Revenue Growth22.44%
EPS Growth23.14%
CountryNZ
Employees126
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)0.14
Shares Outstanding104,874,660
10 Day Avg. Volume21,255
30 Day Avg. Volume23,451
Financial Highlights & Ratios
PEG Ratio0.88
Price to Book (P/B)3.19
Price to Sales (P/S)1.38
P/FCF Ratio-29.69
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.19
Revenue Forecast (FY)$303.00M
AFT Pharmaceuticals Ltd. Business Overview & Revenue Model
Company Description
AFT Pharmaceuticals, along with its subsidiaries, focuses on the creation and distribution of pharmaceutical products across New Zealand, Australia, Asia, and other global markets. Their extensive product range addresses a variety of health catego...
How the Company Makes Money
AFT primarily makes money by commercialising pharmaceutical products and earning revenue from selling those products into various markets. Key revenue streams typically include: (1) Direct product sales where AFT markets and distributes its own br...
AFT Pharmaceuticals Ltd. Financial Statement Overview
Summary
Income Statement
72
Positive
Balance Sheet
66
Positive
Cash Flow
38
Negative
| Breakdown | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 254.71M | 205.49M | 195.41M | 155.82M | 129.83M |
| Gross Profit | 110.55M | 89.19M | 88.27M | 72.16M | 61.30M |
| EBITDA | 28.55M | 21.52M | 27.72M | 20.40M | 21.12M |
| Net Income | 14.73M | 11.96M | 15.61M | 10.65M | 19.85M |
Balance Sheet | |||||
| Total Assets | 217.01M | 169.81M | 165.26M | 148.06M | 121.76M |
| Cash, Cash Equivalents and Short-Term Investments | 10.24M | 11.11M | 12.04M | 4.75M | 7.94M |
| Total Debt | 54.11M | 30.00M | 32.19M | 38.05M | 40.51M |
| Total Liabilities | 107.94M | 72.74M | 77.46M | 74.80M | 65.02M |
| Stockholders Equity | 110.28M | 97.64M | 87.80M | 73.27M | 56.74M |
Cash Flow | |||||
| Free Cash Flow | -11.87M | 6.22M | 16.02M | -173.00K | 6.64M |
| Operating Cash Flow | -11.75M | 13.18M | 25.55M | 9.00M | 12.22M |
| Investing Cash Flow | -9.76M | -6.95M | -9.53M | -9.18M | -5.58M |
| Financing Cash Flow | 11.01M | -6.81M | -10.63M | -6.98M | -3.91M |
AFT Pharmaceuticals Ltd. Technical Analysis
Negative
―
Price Trends
4.43
Negative
4.13
Positive
3.83
Positive
Market Momentum
>-0.01
Negative
46.96
Neutral
45.63
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For NZ:AFT, the sentiment is Negative. The current price of undefined is equal to the 20-day moving average (MA) of 4.32, equal to the 50-day MA of 4.43, and equal to the 200-day MA of 3.83, indicating a neutral trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 46.96 is Neutral, neither overbought nor oversold. The STOCH value of 45.63 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for NZ:AFT.
AFT Pharmaceuticals Ltd. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
80 Outperform | $27.40B | 58.29 | 22.84% | 1.45% | 15.59% | 23.94% | |
60 Neutral | $3.87B | 14.38 | 7.99% | 6.66% | 16.36% | 5.52% | |
54 Neutral | $450.96M | 31.05 | 14.07% | 0.68% | 22.44% | 23.14% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
44 Neutral | $12.57M | -3.87 | -75.57% | ― | 42.20% | 23.68% | |
44 Neutral | $12.67M | -2.80 | ― | ― | 70.82% | 41.04% | |
42 Neutral | $298.05M | -6.27 | -190.54% | ― | -47.36% | -3.79% |
* Healthcare Sector Average
NZ:AFT
AFT Pharmaceuticals Ltd.
4.33
1.52
54.20%
NZ:EBO
EBOS Group Limited
19.14
-8.65
-31.11%
NZ:FPH
Fisher & Paykel Healthcare Corporation Limited
46.50
8.93
23.77%
NZ:PEB
Pacific Edge Limited
0.24
0.04
17.07%
NZ:TRU
TruScreen Group Ltd.
0.01
>-0.01
-29.41%
NZ:RUA
Rua Bioscience Ltd.
0.03
-0.01
-32.43%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.